Bicycle Therapeutics PLC (NASDAQ:BCYC)

48.59
Delayed Data
As of Jan 14
 -0.21 / -0.43%
Today’s Change
20.67
Today|||52-Week Range
62.08
-20.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.4B

Company Description

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Contact Information

Bicycle Therapeutics Plc
Building 900
Cambridge Cambridgeshire CB22 3AT
P:441223261503
Investor Relations:
(617) 447-3948

Employees

Shareholders

Other institutional24.19%
Mutual fund holders16.97%
Individual stakeholders--

Top Executives

Kevin LeeChief Executive Officer & Executive Director
Lee H. KalowskiPresident & Chief Financial Officer
Alistair MilnesChief Operating Officer
Michael SkynnerChief Technology Officer
Nicholas KeenChief Scientific Officer